Drug-induced liver injury: insights from genetic studies.
about
Herbal Hepatotoxicity: Clinical Characteristics and Listing CompilationCase Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryRUCAM in Drug and Herb Induced Liver Injury: The UpdateDrug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment OptionsTranslating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohortGenetic variations in drug-induced liver injury (DILI): resolving the puzzle.Mechanisms of immune-mediated liver injury.Pathologic role of stressed-induced glucocorticoids in drug-induced liver injury in mice.Diagnosis of ABCB11 gene mutations in children with intrahepatic cholestasis using high resolution melting analysis and direct sequencing.Toxicogenetics: population-based testing of drug and chemical safety in mouse models.Risk factors for idiosyncratic drug-induced liver injury.A vector space model approach to identify genetically related diseases.Genetic Variations in TXNRD1 as Potential Predictors of Drug-Induced Liver Injury.Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.Biomarkers for drug-induced liver injury.ROS generated by CYP450, especially CYP2E1, mediate mitochondrial dysfunction induced by tetrandrine in rat hepatocytes.Predicting and preventing acute drug-induced liver injury: what's new in 2010?Adverse drug reactions in women's health care.Bioactivation of herbal constituents: simple alerts in the complex system.Animal models of idiosyncratic drug-induced liver injury--current status.Drug-induced liver injury: the role of drug metabolism and transport.Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease.A web resource for mining HLA associations with adverse drug reactions: HLA-ADRMetabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI).Current challenges and controversies in drug-induced liver injury.Gene expression profiling reveals potential key pathways involved in pyrazinamide-mediated hepatotoxicity in Wistar rats.Acetaminophen-Induced Liver Injury Alters the Acyl Ethanolamine-Based Anti-Inflammatory Signaling System in Liver.TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis.Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractNon-genetic risk factors and predicting efficacy for docetaxel-drug-induced liver injury among metastatic breast cancer patients
P2860
Q26748874-9CAEF31B-DBE3-4595-9206-A665D4FD214CQ26749054-5215E365-08CD-4D7B-BC0D-7F87C062F785Q26771817-90FF1242-5C28-4AC8-B70E-3ED9DDDAE597Q26781892-E6F5009C-13AC-45D6-A269-FAC5DA818D3CQ28478443-22EB1A3F-0D39-4F79-9862-9039084760BBQ28537826-97EF6F2D-AAE9-4AA1-BBCB-833F28D1E2FAQ33354719-730816A8-4100-4673-AC9E-ADD49C20E81CQ33856306-2736321F-1D36-4772-B004-3975C8F48E2DQ33965293-0EC8F391-8D5F-40DA-BEB8-030B60644E58Q34000592-878526E5-32D6-4631-BAD2-CA3857D205EFQ34561910-A7C7423D-3666-40D3-A6E0-2DFF08C79A39Q35168108-C301ECB6-55D4-4490-81FD-FC6CAEA5F50AQ35751203-43006771-3582-4F6F-9245-B1C1BCE26C60Q35895187-20136DCB-1475-4589-B973-7BDBAD95DEEAQ36796350-6E26E258-BB61-4EA3-8726-293E73C8FC33Q37720754-8AFB3ABD-07EF-461A-B465-2D3A376EFF23Q37729578-B9E0568D-EDB4-4C6E-86C2-DA1A070C891FQ37771029-C077D890-B2AD-4186-8633-96EC5696EADCQ37871038-F0BA49C6-9DD2-4C03-8006-41B58C917675Q37879144-ABC9E35E-A10D-49F4-8DAD-646EF2EBAB81Q37897219-8C4898EE-98C4-4304-B38D-AFFFAC11FA99Q38084215-D67E9A53-2E50-4966-8512-C9D2042B4242Q38095989-3DA274BB-C741-4C2B-8E02-C40F34F41DC2Q38099684-4F97EEED-5EF8-44DF-A4DC-657DC84A0F16Q38101884-BFF66E9C-3846-4F0A-8858-63F891FFB9A1Q38539524-0F139D01-70D9-4640-B15E-2137A6AB12A2Q38811345-E5C9E263-4CB2-4ABA-AF21-DDC948609759Q38836848-31E7F28B-E645-4D2E-9A25-66BE1015E825Q39258217-9994ADE6-8F26-4D44-9086-3621ECC3632AQ39523252-0DBF9C2C-688E-4183-8103-33FA044558EEQ39638878-D6746DA2-B4F7-4903-B80D-163F6FA9757FQ45329823-09AE3E7E-B45A-4F9E-A1A0-0939E52AA296Q53395242-E04CA197-D81C-4962-A540-C1CE836D9916Q56984696-51656F35-D67F-4AA8-B088-E786A8A03E7AQ58409646-984A2669-E2DE-4118-A4AF-903CB625294C
P2860
Drug-induced liver injury: insights from genetic studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug-induced liver injury: insights from genetic studies.
@en
Drug-induced liver injury: insights from genetic studies.
@nl
type
label
Drug-induced liver injury: insights from genetic studies.
@en
Drug-induced liver injury: insights from genetic studies.
@nl
prefLabel
Drug-induced liver injury: insights from genetic studies.
@en
Drug-induced liver injury: insights from genetic studies.
@nl
P2093
P2860
P356
P1433
P1476
Drug-induced liver injury: insights from genetic studies
@en
P2093
Eugenia Ulzurrun
M Isabel Lucena
Mercedes Robles
P2860
P304
P356
10.2217/PGS.09.111
P577
2009-09-01T00:00:00Z